Altered expression of 3-betahydroxysterol delta-24-reductase/selective Alzheimer's disease indicator-1 gene in Huntington's disease models

Journal of Endocrinological Investigation

Volumn 37, Issue 8, 2014, Pages 729-737

  Samara, Athina ^a,b   Galbiati, Mariarita ^a   Luciani, Paola ^c   Deledda, Cristiana ^c   Messi, Elio ^a   Peri, Alessandro ^c   Maggi, Roberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cholesterol; DHCR24; Huntingtin; Neurodegeneration; Oxidative stress; Seladin 1

Indexed keywords

3 BETAHYDROXYSTEROL DELTA-24 REDUCTASE; HUNTINGTIN; OXIDOREDUCTASE; POLYGLUTAMINE; UNCLASSIFIED DRUG; 3BETA-HYDROXYSTEROL DELTA24-REDUCTASE; DHCR24 PROTEIN, HUMAN; DHCR24 PROTEIN, MOUSE; HTT PROTEIN, HUMAN; MESSENGER RNA; NERVE PROTEIN; RECOMBINANT PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX ATROPHY; BRAIN TISSUE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MALE; MOUSE; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE; ANIMAL; BRAIN; CELL LINE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PARIETAL LOBE; TRANSGENIC MOUSE; TRINUCLEOTIDE REPEAT;

ADULT; AGED; ANIMALS; BRAIN; CELL LINE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HUNTINGTON DISEASE; MALE; MICE, TRANSGENIC; MIDDLE AGED; NERVE TISSUE PROTEINS; NEURONS; OXIDATIVE STRESS; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PARIETAL LOBE; RATS; RECOMBINANT PROTEINS; RNA, MESSENGER; TRINUCLEOTIDE REPEATS;

EID: 84907367953     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-014-0098-1     Document Type: Article

References (47)

1. Waterham H, Koster J, Romeijn G et al (2001) Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet 69:685-694 (Pubitemid 32868514)
2. Porter FD (2003) Human malformation syndromes due to inborn errors of cholesterol synthesis. Curr Opin Pediatr 15:607-613
3. Greeve I, Hermans-Borgmeyer I, Brellinger C et al (2000) The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci 20:7345-7352
4. Crameri A, Biondi E, Kuehnle K et al (2006) The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. EMBO J 25:432-443 (Pubitemid 43152863)
5. Cecchi C, Rosati F, Pensalfini A et al (2008) Seladin-1/DHCR24 protects neuroblastoma cells against Abeta toxicity by increasing membrane cholesterol content. J Cell Mol Med 12:1990-2002
6. Kuehnle K, Crameri A, Kälin R et al (2008) Prosurvival effect of DHCR24/Seladin-1 in acute and chronic responses to oxidative stress. Mol Cell Biol 28:539-550
7. Peri A, Serio M (2008) Neuroprotective effects of the Alzheimer's disease-related gene seladin-1. J Mol Endocrinol 41:251-261
8. Lu X, Kambe F, Cao X et al (2008) 3beta-Hydroxysteroiddelta24 reductase is a hydrogen peroxide scavenger, protecting cells from oxidative stress-induced apoptosis. Endocrinology 149:3267-3273 (Pubitemid 351919585)
9. Peri A, Benvenuti S, Luciani P, Deledda C, Cellai I (2011) Membrane cholesterol as a mediator of the neuroprotective effects of estrogens. Neuroscience 191:107-117
10. Numakawa T, Matsumoto T, Numakawa Y, Richards M, Yamawaki S, Kunugi H (2011) Protective action of neurotrophic factors and estrogen against oxidative stress-mediated neurodegeneration. J Toxicol 2011:405194
11. Sharpe LJ, Wong J, Garner B, Halliday GM, Brown AJ (2012) Is seladin-1 really a selective Alzheimer's disease indicator? J Alzheimers Dis 30:35-39
12. The Huntington Disease Collaborative Research (1993) G. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983
13. Rigamonti D, Bauer JH, De-Fraja C et al (2000) Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20:3705-3713 (Pubitemid 30266233)
14. Rigamonti D, Sipione S, Goffredo D, Zuccato C, Fossale E, Cattaneo E (2001) Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J Biol Chem 276:14545-14548
15. Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90:905-981
16. Saleh N, Moutereau S, Durr A et al (2009) Neuroendocrine disturbances in Huntington's disease. PLoS One 4:e4962
17. Petersén A, Björkqvist M (2006) Hypothalamic-endocrine aspects in Huntington's disease. Eur J Neurosci 24:961-967
18. Browne SE, Beal MF (2006) Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 8:2061-2073 (Pubitemid 46489631)
19. Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S (2001) Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 24:182-188 (Pubitemid 32166824)
20. Sipione S, Rigamonti D, Valenza M et al (2002) Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet 11:1953-1965 (Pubitemid 34919271)
21. Valenza M, Leoni V, Tarditi A et al (2007) Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 28:133-142 (Pubitemid 47429978)
22. Valenza M, Leoni V, Karasinska JM et al (2010) Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes. J Neurosci 30:10844-10850
23. Leoni V, Mariotti C, Nanetti L et al (2011) Whole body cholesterol metabolism is impaired in Huntington's disease. Neurosci Lett 494:245-249
24. Valenza M, Rigamonti D, Goffredo D et al (2005) Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 25:9932-9939 (Pubitemid 41528031)
25. Leoni V, Mariotti C, Tabrizi SJ et al (2008) Plasma 24S- hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 131:2851-2859
26. Ermak G, Hench KJ, Chang KT, Sachdev S, Davies KJ (2009) Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro. J Biol Chem 284:11845-11853
27. Mangiarini L, Sathasivam K, Seller M et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506 (Pubitemid 26374323)
28. Rigamonti D, Bolognini D, Mutti C et al (2007) Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators. J Biol Chem 282:24554-24562 (Pubitemid 47347498)
29. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
30. DiFiglia M, Sapp E, Chase KO et al (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-1993 (Pubitemid 27449140)
31. Carter RJ, Lione LA, Humby T et al (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19:3248-3257 (Pubitemid 29174016)
32. Quinti L, Chopra V, Rotili D, et al. (2010) Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knockin HD mouse models and human patients and in a neuronal HD cell model. PLoS Curr 2. doi:10.1371/currents.RRN1172
33. Bowles KR, Brooks SP, Dunnett SB, Jones L (2012) Gene expression and behaviour in mouse models of HD. Brain Res Bull 88:276-284
34. Vonsattel JP, Keller C (2008) Del Pilar Amaya M. Neuropathology of Huntington's disease. Handb Clin Neurol 89:599-618
35. Kuhn A, Goldstein DR, Hodges A et al (2007) Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 16:1845-1861 (Pubitemid 47244533)
36. Sarchielli E, Marini M, Ambrosini S, et al. (2014) Multifaceted roles of BDNF and FGF2 in human striatal primordium development. An in vitro study. Exp Neurol 257C:130-147
37. Katsuno M, Adachi H, Sobue G (2009) Getting a handle on Huntington's disease: the case for cholesterol. Nat Med 15:253-254
38. Wu C, Miloslavskaya I, Demontis S, Maestro R, Galaktionov K (2004) Regulation of cellular response to oncogenic and oxidative stress by Seladin-1. Nature 432:640-645 (Pubitemid 39626272)
39. McGrath K, Li X, Puranik R et al (2009) Role of 3beta-hydroxysteroid- delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 29:877-882
40. Otis M, Battista M, Provencher M et al (2008) From integrative signalling to metabolic disorders. J Steroid Biochem Mol Biol 109:224-229
41. Sarkar D, Imai T, Kambe F et al (2001) The human homolog of Diminuto/Dwarf1 gene (hDiminuto): a novel ACTH-responsive gene overexpressed in benign cortisol-producing adrenocortical adenomas. J Clin Endocrinol Metab 86:5130-5137 (Pubitemid 33070226)
42. Chae JI, Kim DW, Lee N et al (2012) Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem J 446:359-371
43. Illuzzi JL, Vickers CA, Kmiec EB (2011) Modifications of p53 and the DNA damage response in cells expressing mutant form of the protein huntingtin. J Mol Neurosci 45:256-268
44. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44:559-577 (Pubitemid 16196286)
45. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR (1993) Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 43:2689-2695 (Pubitemid 24004570)
46. Rajkowska G, Selemon LD, Goldman-Rakic PS (1998) Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 55:215-224
47. Nieweg K, Schaller H, Pfrieger FW (2009) Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J Neurochem 109:125-134